Active	Status	Sponsor type	Region	Phase	Filter
12 Active 9 Inactive 21 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
obexelimab (ZB012) / Zenas BioPharma
INDIGO, NCT05662241: A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease	Recruiting	3	200	Europe, Canada, Japan, US, RoW	Obexelimab, Placebo	Zenas BioPharma (USA), LLC	IgG4 Related Disease	10/25	12/26
NCT05786573: A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)	Recruiting	3	134	Europe, Japan, US, RoW	Obexelimab, Placebo	Zenas BioPharma (USA), LLC	Warm Autoimmune Hemolytic Anemia	03/26	06/26
NCT06564311: A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)	Recruiting	2	93	US	Obexelimab, Placebo	Zenas BioPharma (USA), LLC	Relapsing Multiple Sclerosis	08/25	12/25
SunStone, NCT06559163: A Study of Obexelimab in Patients with Systemic Lupus Erythematosus	Recruiting	2	190	US	Obexelimab, Placebo	Zenas BioPharma (USA), LLC	Systemic Lupus Erythematosus	11/25	03/26
VRDN-001 / Viridian Therap
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies	Recruiting	3	143	Europe, US	Intervention/Treatment	Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/25	03/26
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)	Recruiting	3	212	US	VRDN-001 10 mg/kg, VRDN-001 3 mg/kg	Viridian Therapeutics, Inc.	Thyroid Eye Disease	05/25	01/26
THRIVE, NCT05176639: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)	Active, not recruiting	3	188	Europe, US, RoW	Veligrotug (VRDN-001), Placebo	Viridian Therapeutics, Inc.	Thyroid Eye Disease	12/24	09/25
2021-006794-37: A Safety, Tolerability and Efficacy Study of VRDN 001	Not yet recruiting	2/3	184	Europe	VRDN-001, VRDN-001, Concentrate for solution for infusion	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid eye disease (TED), Thyroid eye disease (TED), Diseases [C] - Eye Diseases [C11]
NCT05542303: A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects	Completed	1	24	RoW	ZB001 for injection	Zenas BioPharma (USA), LLC	Healthy Volunteers	04/23	04/23
NCT05776121: Study of ZB001 in Chinese Patients With Thyroid Eye Disease	Active, not recruiting	1	17	RoW	ZB001 for injection	Zenas BioPharma (USA), LLC	Thyroid Eye Disease	10/24	10/24
adalimumab biobetter (ZB002) / Zenas BioPharma
NCT05638854: A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants with Rheumatoid Arthritis	Recruiting	1	72	RoW	ZB002, Placebo	Zenas BioPharma (USA), LLC	Healthy Volunteers, Rheumatoid Arthritis	07/25	07/25